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More frequent, more costly? Health
economic modelling aspects of monitoring
glaucoma patients in England
Trishal Boodhna and David P. Crabb*
Abstract
Background: Chronic open angle glaucoma (COAG) is an age-related eye disease causing irreversible loss of visual
field (VF). Health service delivery for COAG is challenging given the large number of diagnosed patients requiring
lifelong periodic monitoring by hospital eye services. Yet frequent examination better determines disease
worsening and speed of VF loss under treatment. We examine the cost-effectiveness of increasing frequency of VF
examinations during follow-up using a health economic model.
Methods: Two different VF monitoring schemes defined as current practice (annual VF testing) and proposed
practice (three VF tests per year in the first 2 years after diagnosis) were examined. A purpose written health economic
Markov model is used to test the hypothesis that cost effectiveness improves by implementing proposed practice on
groups of patients stratified by age and severity of COAG. Further, a new component of the model, estimating costs of
visual impairment, was added. Results were derived from a simulated cohort of 10000 patients with quality-adjusted
life years (QALYs) and incremental cost-effectiveness ratios (ICERs) used as main outcome measures.
Results: An ICER of £21,392 per QALY was derived for proposed practice improving to a value of £11,382 once savings
for prevented visual impairment was added to the model. Proposed practice was more cost-effective in younger
patients. Proposed practice for patients with advanced disease at diagnosis generated ICERs > £60,000 per QALY; these
cases would likely be on the most intensive treatment pathway making clinical information on speed of VF loss
redundant. Sensitivity analysis indicated results to be robust in relation to hypothetical willingness to pay threshold
identified by national guidelines, although greatest uncertainty was allied to estimates of implementation and visual
impairment costs.
Conclusion: Increasing VF monitoring at the earliest stages of follow-up for COAG appears to be cost-effective
depending on reasonable assumptions about implementation costs. Our health economic model highlights
benefits of stratifying patients to more or less monitoring based on age and stage of disease at diagnosis;
a prospective study is needed to prove these findings. Further, this works highlights gaps in knowledge
about long term costs of visual impairment.
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Background
Chronic open-angle glaucoma (COAG) is an age-related
eye disease of the optic nerve [1]. Early onset COAG is
typically asymptomatic but as it advances so does the
risk of irreversible loss of sight. Visual impairment in
COAG, manifesting as loss of visual field (VF), may be
associated with restricted mobility, falls, motor vehicle
accidents and reduced quality of life [2, 3]. Furthermore,
COAG is the second major cause for blind registration
in the United Kingdom (UK) [4]. In the UK around 2 %
of people over 40 years have COAG, rising to almost
10 % in people over 75 years [5]. With an aging popula-
tion the number of people affected by COAG will in-
crease. Fortunately, most patients respond to treatment
and only a minority go on to develop visual impairment
[6]. Yet, once diagnosed, all patients require lifelong
clinical follow-up so that any worsening of disease can
be detected and treatment intensified accordingly.
Monitoring COAG in secondary care (hospital eye services)
focuses upon the evaluation of the VF, assessment of
the optic nerve and measurement of the elevation of in-
traocular pressure (IOP). The latter is the only treatable
risk factor for VF deterioration (progression) [7]. In
some patients only modest pharmacological treatment
may be required since progression is static or slow,
while in others it may be very difficult to control rapidly
progressive disease.
The lifelong nature of glaucoma follow-up means
there are long-term economic implications. Glaucoma
patients cause considerable direct costs to the UK
National Health Service (NHS) due to monitoring expen-
ditures, costs of medication, procedures and outpatient
clinic visits. In England and Wales alone, it has been
estimated that there are more than one million glaucoma
related visits to hospital eye service every year [5]. In
addition to this direct burden, considerable indirect costs
are also incurred as a consequence of progression to po-
tential visual impairment and blindness [8, 9]. Significant
trends between the costs and severity of disease have been
reported [10–12]. As such, a potential economic argument
accompanies the clinical reasoning for increased monitor-
ing of patients with glaucoma in order to potentially
reduce the number of patients progressing to serious
sight loss [13].
In short, VF testing aims to locate damaged areas in a
patient’s field of vision using a technique, called perim-
etry, that systematically measures the patient’s ability to
identify the presence of a small spot of light [14]. The
computerised instrument produces a map of VF loss in
each eye. Changes in these maps between follow-up
visits can be used to assess VF progression or stability.
Patients with fast VF progression are in greater danger
of visual impairment, in a given time-frame, than pa-
tients with slow progression. Therefore, VF monitoring
is an important component in the management of a pa-
tient. However, VF testing produces variable measure-
ments which necessitate frequent monitoring or a
considerable period of time to precisely detect true dis-
ease progression. Several studies have shown increasing
the frequency of VF testing (more examinations per
year) at different stages of follow-up leads to earlier de-
tection of progression [13, 15–18]. Simply put, an ad-
equate number of VF tests must be performed over a
given period in order to separate true disease progression
from the measurement variability inherent in VF data.
Nevertheless, frequency of monitoring presents a dilemma
for health service delivery for patients with COAG: if VF
changes are not detected early enough, because of infre-
quent testing, there might be long term costs associated
with the disease progression following inadequate treat-
ment; on the other hand, if patients are examined too
often there is increased pressure on clinic resources. It is
this dilemma that is examined in this report.
The best way to examine different monitoring schemes
would be with a randomised clinical trial. No such study
has been performed and it would likely be substantial
and costly. The first step ought to involve some modelling
of existing data. We previously examined the cost-
effectiveness of using different monitoring intervals to
detect VF progression rates in all newly-diagnosed
COAG patients using a health economic model developed
for the purpose [19]. Two different VF monitoring schemes
defined as current practice (annual VF testing) and pro-
posed practice (three VF tests per year in the first 2 years
after diagnosis) were examined. We now update aspects of
the model to examine the hypothesis that cost effectiveness
improves by implementing proposed practice on groups of
patients stratified by age and severity of glaucoma at diag-
nosis. Further, a new component of the model, estimating
costs of visual impairment, is added. We hypothesise that
proposed practice applied to some groups of patients will
yield improved clinical information and therefore increase
the cost-effectiveness of clinical care. The outcome of this
economic evaluation could potentially provide information
to assist decision-makers in the allocation of the available
resources so that benefits can be maximised; it could also
be used to help design an appropriate prospective study on
frequency of monitoring in glaucoma.
Methods
In this section we first outline the national guidelines for
determining cost-effectiveness of clinical intervention.
Then we outline the difference between current practice
and proposed practice for VF follow-up in COAG. Next
we briefly describe our health economic model, since
the details are published elsewhere [19]; this review in-
cludes a brief description of how treatment pathways are
adapted given what we define as perfect information
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about observed disease progression that might be better
afforded by the increased monitoring in proposed prac-
tice. New updates to the published model, including
costs for visual impairment, are also described. The
model is then used in a novel fashion to experiment with
applying proposed practice to groups of patients strati-
fied by age and disease severity at diagnosis. Finally, in
sensitivity analysis, we explore the impact of changing
model parameters.
National guidelines for cost-effectiveness of clinical
intervention
In England and Wales, the National Institute for Health
and Care Excellence (NICE) is responsible for establish-
ing evidence based guidelines for clinical practice and
recommendations about resource allocation within the
NHS. NICE also attempts to assess the cost-effectiveness
of potential expenditures within the NHS. For example,
benefits associated with different interventions are typically
assessed using the quality adjusted life year (QALY)
and the derivation of incremental cost-effectiveness
ratios (ICERs) [20]; these identify the cost with which an
extra QALY is produced by the new intervention which
can then be compared against the willingness to pay for
these units of health benefit in the NHS. ICERs of £20,000
or lower per QALY are thought to be acceptable, with
ICERs between £20,000 and £30,000 also having a high
probability of acceptance by NICE [21, 22].
Definition of current practice and proposed practice
Recommendations for frequency of follow-up for pa-
tients diagnosed with COAG in England and Wales
(NHS) have been set by NICE [5]. Following diagnosis,
long term monitoring of IOP, assessment of the optic
nerve and the VF is required. Monitoring intervals are
recommended according to risk of progression, control
of IOP and treatment. These intervals range from 3 to
12 months and more detail can be found elsewhere [5].
However, VF monitoring intervals assigned by clinicians
for hypothetical patient scenarios have been shown to be
variable [23]. In addition, audit data from six hospitals in
England showed most patients only get two or three VF
examinations in the first two years after diagnosis [24].
More recently we examined a very large number of
COAG patient appointments in electronic patient records
from four different centres in England and found most pa-
tients get an annual VF examination only [25]. For these
reasons we make the simplifying assumption that after
diagnosis of COAG annual testing of the VF is current
practice.
Several studies have suggested increasing the fre-
quency of VF examinations, at different points in follow-
up, may lead to better detection of glaucoma progression
[13, 15–18]. Specifically it has been recommended that
newly-diagnosed patients should undergo VF testing
three times per year in the first 2 years after diagnosis
[13]. This frequency of testing identifies rapidly progres-
sing eyes with greater certainty than if annual testing
was implemented and can help characterise clinically
important information about speed (rate) of disease
progression. The latter, coupled with a patient’s age, is im-
portant in order to determine lifetime risk of visual im-
pairment and ought to lead to better clinical management
decisions. The recommendation of six VF examinations in
the first 2 years after diagnosis, recently adopted in the
European Glaucoma Society (EGS) guidelines on patient
examination for COAG [26], is defined as proposed
practice (see Fig. 1). (It is important to note current EGS
guidelines simultaneously recognize there is no solid
evidence for optimum monitoring schemes for patients
with COAG. Furthermore some evidence considered by
the guidelines also questions the value of more frequent
monitoring [26]).
For the purpose of this work, VF progression was de-
fined as a reduction in the mean deviation (MD) index
(dB/year). MD is conventionally used in the clinic and in
clinical trials; it is a summary measure of the overall re-
duction in VF sensitivity relative to a group of healthy
age-matched observers with more negative values indicat-
ing more vision loss [14]. Time period (years) required to
detect various rates of MD change in VFs were calculated
via extensive simulations and the results of these are
published elsewhere [19, 27]. In short, detection time
of disease progression is potentially delayed, on average,
Fig. 1 Schematic illustrating the time points at which VF examinations could be performed under current practice and proposed practice up to
4 years. Proposed practice detects progression earlier but comes at the costs of more testing
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by about two years with current practice compared to
proposed practice. This difference in detection time
might provide more timely intervention but at the cost of
more testing, and hospital visits, in the initial two years of
follow-up.
Health economic model
The health economic model was purpose written in
Microsoft Excel, and is described extensively elsewhere
in an open-access National Institute for Health Research
(NIHR) report [19]. From this point we refer to this as
the frequency of VF monitoring (FVFM) model. Now we
summarise the main features of the FVFM model and
only detail aspects that we have newly updated.
FVFM uses a Markov model to compare proposed
practice against current practice for patients with newly
diagnosed COAG during a 25-year horizon. Markov
models are commonly used for quantifying the costs and
health consequences of patients moving through different
disease stages over time [20, 28, 29].
In the model, patients can start in any one of four
states of severity of disease at diagnosis. We assume that
one cycle through the Markov model is 1-year long. In
each cycle through the model, the costs and utilities are
calculated for each cohort of patients. In a particular
model cycle, patients can remain within their existing
health state, or progress towards a worse health state.
Progression towards a worse disease severity is the only
possible transition because vision loss in COAG is irre-
versible. It is also assumed that patients move sequen-
tially and cannot skip states due to the slow evolution of
the disease. Patients may also leave the model and move
into an absorbing state (‘Death’). All-cause mortality is
incorporated throughout every cycle of the Markov
model. Data was sourced on life expectancy and annual
membership of the model was adjusted to account for a
certain proportion of patients leaving the model due to
all-cause mortality (See Fig. 2).
The disease process in glaucoma is a complex multi-
variable one and long-term outcomes for individuals are
often unpredictable. For our model, we only conceptualise
disease progression and its treatment as they manifest in
clinical practice. First, the model is only applicable to pa-
tients that have a diagnosis of COAG as defined by NICE
and is not relevant to patients with a diagnosis of ocular-
hypertension or others that are at risk of glaucoma. Next,
VF damage alone is used as a proxy for glaucoma disease
severity. Disease progression is modelled by means of the
speed (rate) at which the MD worsens. Then, we make the
simplifying assumption that the effect of treatment lowers
IOP, which in turn affects the VF progression rate and re-
duces the movement between the disease states. The
model then assesses the impact of being able to institute
treatment decisions earlier because of the better clinical
information afforded by the proposed practice compared
to current practice.
In order to reduce model complexity and allow simple
decisions about treatment pathways we assume that a
patient can be characterised according to four categorical
variables at the point of diagnosis of COAG:
 Age (younger patient; older patient)
 Severity of disease (mild; moderate; severe; visually
impaired)
 Rate of progression (stable; slow; medium; fast)
 Risk of progression (high risk; typical risk)
Age of patient is reduced to a dichotomous variable –
the modelled younger and older patient has an age of 50
and 70 years at diagnosis respectively, making up 28.2
and 71.8 % of the cohort respectively. The rationale for
these values and distribution is detailed in the descrip-
tion of the FVFM model. Severity of Disease (health
states) was defined according to a commonly used classi-
fication of MD [30]. Conveniently this scheme has been
used in previous health economic models of glaucoma
health service delivery and, importantly for our purposes,
allows for use of utilities reported elsewhere [31–33]. Mild
disease is defined as VF loss with an MD better than -6 dB.
Moderate disease is defined as VF loss with an MD
Fig. 2 A schematic of the Markov Model for a glaucoma disease ’pathway’
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between -6 dB and -12 dB. Severe disease is defined as VF
loss with an MD between -12 dB and -20 dB; very few of
these patients would satisfy the visual field component for
legal fitness to drive for example [34]. Of course, people
function visually with both eyes and the better seeing eye
is the best estimate of visual function [35]. Therefore,
these levels of disease severity were required to exist in
the patient’s better eye (defined as the eye with the better
MD) since this best reflects the patients visual morbidity
[36]. Patients with MDs worse than -20 dB were classified
as visually impaired [12, 37].
Rate (Speed) of progression in an individual patient can
be estimated from MD loss per year for patients using
linear regression of MD against time [25]. The more
negative the rate the faster the progression speed.
These rates are categorised as stable (≥0 dB/year),
slow (between 0 and -0.5 dB/year), medium (between -0.5
and -1.5 dB/year) or fast (worse than -1.5 dB/year). It is
important to note that observed rate of progression is only
available to the clinician in our model when sufficient VFs
have been done to precisely detect it - this is termed
‘perfect information’. It is therefore this variable that
varies between proposed and current practice.
Risk of progression in COAG is nebulous and multifac-
torial. Apart from level of IOP, risk of progression is
composed among other factors of baseline diagnosis of
exfoliation syndrome, decreased corneal thickness, struc-
tural changes to the optic nerve head and the retinal
nerve fibre layer and co-morbidity of other eye diseases
[1]. For our model we took the simplifying step of denot-
ing patients to have high progression risk or typical pro-
gression risk and the input parameters were taken from
the FVFM model.
Consequently, at diagnosis of COAG, there are 64
types of ‘patients’ based on the permutations of the ini-
tial model parameters. The relative proportions belong-
ing to each group were estimated from data observed in
glaucoma clinics in England. For this report figures for
severity of disease and rate of progression were newly
updated following recently published work and these are
summarised in Table 1 [25, 38].
The model simulates glaucoma progression in 10,000
hypothetical COAG patients stratified by age (50 and
70 years) and severity of glaucoma at diagnosis. The prob-
ability of transition to the next state in the model followed
published methodology of Hernández et al. [32] and Briggs
et al. [20]; these are driven by the treatment pathways that
are used to ameliorate the rate of progression. Again, these
are detailed elsewhere [5, 19] but what follows is a short
description of the principles underpinning them.
People newly diagnosed with COAG are offered
‘pharmacological treatment’ and this is denoted treatment
pathway 1. Patients with COAG who are at risk of pro-
gressing to visual impairment despite this first line treat-
ment are offered intensified treatment which might be
surgery with pharmacological augmentation. Typically,
this would only be done after an observing evidence of
disease progression. It is this information that might be
yielded earlier by proposed practice. In the FVFM model
this intensified treatment pathway is denoted as 2 or 3.
For our purposes the former would typically be combina-
tions of alternative pharmacological treatments or ‘laser
treatment’ whereas the latter would be trabeculectomy
with pharmacological augmentation. To model the deci-
sion making process behind treatment allocation and its
impact upon the probability of transition to worse states
Table 1 Parameters for our updated model were estimated from a retrospective analysis of an electronic patient record containing
473,252 VFs downloaded in 2012 from Moorfields Eye Hospital in London; Cheltenham General Hospital Gloucestershire Eye Unit;
Queen Alexandra Hospital in Portsmouth and the Calderdale and Huddersfield NHS Foundation Trust
Parameter Stratification 50 y/o 70 y/o
Progression Rate Distributiona Stable (0 dB/year) 46.7 % 37.9 %
Slow (-0.25 dB/year) 37.8 % 36.6 %
Medium (-1 dB/year) 12.5 % 19.1 %
Fast (-1.5 dB/year) 3.0 % 6.4 %
Health State Distributionsb Mild (> -6 dB) 83.0 % 79.8 %
Moderate (-6 dB to -12 dB) 10.8 % 15.0 %
Severe (-12 dB to -20 dB) 5.6 % 4.1 %
Visually Impaired (<-20 dB) 0.6 % 1.1 %
Initial Damagec Mild −3.1 dB −3.1 dB
Moderate −8.3 dB −8.4 dB
Severe −15.5 dB −15.4 dB
Visually Impaired −24.0 dB −23.6 dB
Baseline progression rate and existing damage in the better eye were revised following methods used in two studies using this dataset to examine levels of rates
of loss and existing disease severity distributions at diagnosis (a = [25] ; b = [38]; c = FVFM Model [19])
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of disease, two ophthalmologists with a specialist interest
in glaucoma, were consulted to construct simplified treat-
ment pathways that patients would face in a NHS hospital
setting [19].
For the FVFM model the treatment pathways are used
in a time period denoted as ’imperfect information‘,
where the managing clinician is ‘unaware’ of the patient’s
true rate of VF progression, simply because they have
not been monitored closely enough. After a defined
number of VF tests, we identify the patient’s progression
rate, and then enter into a time period defined as ‘perfect
information’. The clinician now has the opportunity to
continue to provide the patient with the existing degree
of treatment, or to intensify it. These pathways are
linked by a series of decision nodes detailed in the
FVFM model. As an example, a younger patient entering
into glaucoma care at health state 1 (mild damage) and
defined as being at low risk of progression would receive
treatment pathway 1. If the patient was subsequently de-
fined as having a fast rate of progression then they
would be moved to 3rd line treatment but only when
the clinician has ‘perfect information’. This functionality
was built into the model in order to reflect the resource
reallocation that occurs once the clinician identifies
those patients who are potentially undertreated. This
temporal improvement in patient management is what
underpins this study, as the more expedient allocation of
efficient treatment modalities differentiates the proposed
practice from current practice. However, this reallocation
comes at a cost and this is described briefly below.
A key component of the cost-effectiveness of proposed
practice is the cost of additional resources for more VF
testing. After all, this is seen as the main barrier for
implementing increased surveillance and more examina-
tions [23]. Costs were sourced from the reference costs
[39] and along with the costs of treatment, (derived from
a study reported by Traverso et al. [10]) are taken
directly from those used in the FVFM model. (Costs for
extra VF testing associated with proposed practice did not
consider personal costs to the patient such as travel or
absence from work for extra clinic appointments.)
Of course a key driver of the cost-effectiveness of the
proposed practice is the quality-of-life improvement
gained from reducing the chances of VF loss and visual
impairment. In this study, utility weights associated with
each health state were derived from those developed and
implemented by Burr and colleagues [31, 40]. Conse-
quently, those defined with mild, moderate, severe dis-
ease and visual impairment were attributed a utility of
0.8015, 0.7471, 0.7133 and 0.5350 per year respectively.
Model analysis
Our main outcome measure was the ICER derived by
proposed practice as an alternative to current practice as
applied to all newly diagnosed patients (full model). A
further outcome measure was the years of healthy vision
saved with proposed practice compared to current prac-
tice. We then stratified the patient into four groups as
described in Fig. 3. Each of the four groups was mod-
elled separately to receive proposed practice while all
other patients would receive current practice. The model
results, with the ICER being the primary outcome, were
then used to test the hypothesis that applying proposed
practice to a specific group of patients would be more
cost-effective than making it available to all newly diag-
nosed patients.
In the FVFM model we did not include indirect costs
of severe visual impairment from COAG. These are
governmental and societal costs for supporting a visually
impaired person, such as visual rehabilitation, social ser-
vices, or local authority care rather than costs of blindness
to the individual. Estimating these costs is problematic,
country dependent and tricky to establish [41]. Still, some
useful estimates are available [8]; these costs were inflated
to 2015 levels using the retail price index and were
Fig. 3 An illustration of the subgroup stratifications used for further
cost-effectiveness analysis. Patients were stratified by merging health
state groups into what we loosely describe as ‘Late’ disease (severe
or worse VF loss in the better eye) or ‘Non-Late’ (‘Early’) Disease (mild
and moderate VF loss in better eye)). The former would be patients
diagnosed with a level of vision loss that would likely be incompatible
with the VF component for legal fitness to drive in the UK [34]. Age
distribution was taken directly from that used in the FVFM model. In
the model proposed practice was provided to each of the four
individual groups in turn with the remaining groups being allocated to
the current practice
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identified as ranging between £1,375 and £17,100 for the
first year of blindness and £1,325 and £16,800 for each
subsequent year thereafter. We incorporated the most
conservative estimate from the range identified because of
the uncertainty of the estimates as applied to glaucoma
blindness. As such, a modest cost of £1,777 was used in
the updated model to represent the economic burden of
progression to visual impairment.
Sensitivity analyses were performed in order to exam-
ine how parameter uncertainty interacted with model
outcomes [42, 43]. Preliminary sensitivity analysis was
performed at the earliest stages of model development in
order to facilitate the understanding of how inputs interact
with model outcomes. One-way deterministic sensitivity
analysis (DSA) and probabilistic sensitivity analysis (PSA)
were performed on the outputs generated by the Markov
model once rationality in these outputs was assumed.
From the derived ICERs, incremental cost-effectiveness
planes were constructed and from these cost-effectiveness
acceptability curves (CEACs) were drawn indicating the
probability of proposed practice being accepted at given
levels of willingness to pay [20, 44].
Ethics approval for this modelling exercise was not re-
quired. Access to the non-identifiable patient data sum-
marized in Table 1 was granted by the Caldicott Guardian
at each participating centre and is described elsewhere
[25, 38]. Subsequent analyses of the data, including that
done in this work, were approved by a research ethics
committee of City University London.
Results
In total, 10,000 patients were simulated to enter into the
health economic model with a positive cost differential
of £298 per patient identified between proposed practice
and current practice (Table 2). This implies higher costs
with proposed practice but this corresponds with a posi-
tive utility differential (0.014 QALYS per patient). Con-
sequently an ICER of £21,392 per QALY was derived for
proposed practice, a figure within the hypothetical NICE
ceiling ratio of £30,000. Furthermore, a total of 785 vis-
ual impairment years were saved as a result of increased
early monitoring associated with the proposed practice
across the 25-year time horizon. These results are relevant
to applying proposed practice to all newly diagnosed pa-
tients. Table 2 summarises the results for the scenarios
when proposed practice is allocated to four specific sub-
groups of patients.
The best ICER associated with proposed practice was
yielded from the younger cohort diagnosed with early
(to moderate) stage VF loss in their better eye. Worse
ICERs, incompatible with hypothetical willingness to pay
thresholds, are returned for those patients that are
already at an advanced disease state on diagnosis in their
better eye.
After annual costs of visual impairment (£1,777 per
year) were incorporated into the model, an incremental
cost of £159 per patient (incremental utility of 0.14) was
identified between proposed practice and current prac-
tice. There is no change in terms of incremental QALYs
given that societal costs of visual impairment do not im-
pact upon the patient themselves, so this yielded an
ICER of £11,382 per QALY being derived for proposed
practice. This represents a significant reduction in the
ICER compared to result without visual impairment
costs added. The latter were then varied to identify the
threshold for cost neutrality between the current practice
and proposed practice across both the full simulation.
Under the full simulation, a value of £3,798 was identi-
fied as the required costs of visual impairment to equate
proposed practice to current practice.
Sensitivity analysis
DSA results are presented in a Tornado diagram for the
full simulation (Fig. 4). The horizontal axis is the out-
come (the ICER for allocating current practice to all
newly diagnosed patients); along the vertical axis, pa-
rameters are ordered and horizontal bars represent the
outcome range associated with the specified parameter’s
range (maximum and minimum value limits impact
upon ICERs). For all parameters, outcomes were sorted
in order of ICER impact. The uncertainty surrounding
the implementation cost parameter and the visual im-
pairment cost parameter resulted in the highest ICER
variations but neither were sufficient enough to push the
ICER beyond the £30,000/QALY ceiling ratio. For ex-
ample, the maximum identified limit for implementation
costs (£2.26 m) resulted in an ICER of £24,600. Tellingly,
the next most important parameters were the treatment
costs and utility health states followed by the distribu-
tions of the existing damage. Progression rates were
found to have very little impact despite being varied by
10 % in either direction.
Unsurprisingly, in the PSA (see Fig. 5), greater cost-
effectiveness was observed when costs of visual impair-
ment were included (b) compared to when it was not (a).
The observations in (b) are lower on the plane (indicating
Table 2 ICERs produced once the proposed practice was
provided to specific subgroups stratified by age and glaucoma
severity
Age subgroup Severity
subgroup
Incremental
costs
Incremental
utility
ICER
All All £298 0.014 £21,392
Younger patient Early £306 0.021 £14,797
Late £3,251 0.049 £66,219
Older patient Early £287 0.014 £21,024
Late £4,170 0.030 £138,891
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lower costs) with little change in the width of the observa-
tions (indicating similar effectiveness). Proposed practice
in younger patients with early glaucoma (c), placed obser-
vations significantly lower on the plane than in the simple
model (a), indicating a significant improvement on cost-
effectiveness. Patients (both young and old) with advanced
glaucoma yielded a compressed cluster of observations.
Simply, the model is inferring that those with late glau-
coma have less vision to save; therefore, less incremental
utility can be derived. For older patients with early glau-
coma (e), observations were more spread across the cost-
effectiveness plane suggesting greater likelihood of utility
gain given their greater preserved vision.
CEACS were derived from these simulations (see Fig. 6).
Willingness to pay for each QALY gained was varied from
£0 to £50,000 and the proportion of simulations deemed
acceptable at this level were recorded. Similar shaped
CEACs were observed for the model with and without the
visual impairment costs added. However, the shift of the
CEAC to the left for the model with visual impairment
costs included indicates an increased probability of accept-
ance of this scenario. At the £30,000 per QALY ceiling ra-
tio, the proposed practice was acceptable 82 % of the time
when these indirect costs were modelled whilst only 65 %
of the time when they were not. When proposed practice
was provided to patients with early glaucoma, there was
less deviation from the simple model with 70 % (old) and
74 % (young) being observed to be acceptable at the
£30,000 per QALY ratio. CEACs trail close to zero for the
patients diagnosed with late disease indicating a significant
lack of cost-effectiveness likelihood for these subgroups.
Discussion
This modelling exercise primarily sought to examine
whether increased VF monitoring at the earliest stages
of disease identification in COAG (i.e. six VFs in the first
2 years after diagnosis) would be cost-effective compared
with the assumed current practice of one VF per year.
An ICER of £21,392 indicates that the proposed practice
is a cost-effective strategy for all patients given a hypo-
thetical £30,000/QALY NICE acceptability ceiling ratio.
So these health economic findings support the EGS
guideline recommendation of undertaking 6 VFs in the
first 2 years after glaucoma diagnosis.
Introduction of costs of visual impairment further in-
creased the cost-effectiveness of the proposed practice. A
Fig. 4 Tornado Diagram measuring the impact in variation in parameters for the health economic model with included visual impairment costs
(ICER = £11,382). Maximum and minimum limits for parameters were identified. ICERs were derived and ordered in terms of impact (greatest to
lowest ICER variation)
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cost of visual impairment threshold of £3,798 per year
was identified as the minimum value required ensuring
that the proposed practice would equate to current prac-
tice in terms of costs across the full 25 year time horizon
of the model. Put another way, if cost of visual impair-
ment per year is assumed to be greater than £3,798 per
year then, proposed practice is preferable to current
practice. This figure sits at the lower end of the distribu-
tion of the costs estimated in the Meads et al. study
(£1,325 to £16,800 per year throughout the duration of
patients residual lifetime) [8]. Moreover other studies
have estimated costs of visual impairment to be signifi-
cantly greater. For example Lafuma and colleagues re-
ported a value of €13,674/year in the UK in 2006 (equating
to about £11,000/year when inflated to 2015 values and
converted to pound sterling) and Burr et al. suggested the
figure could be as high as £40,000/year [33, 45]. Therefore,
if we were to use the values found in these alternative stud-
ies, the proposed practice would be the cheaper long term
patient pathway compared to current practice due to the
costs saved by reducing the amount of patients progressing
Fig. 5 Cost-Effectiveness Planes for the different subgroups analysed
Fig. 6 Cost Effectiveness Acceptability Curves across the
subgroups analysed
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to visual impairment over the 25 years (an ICER of £11,383
per QALY). We think this is a significant finding. More-
over, our report should stimulate more research into the
hidden costs of burden of sight loss and encourage other
researchers to include them in their health economic
models when studying conditions that lead to sight loss.
We haven’t included them all. For instance, ‘hidden’ costs
arise because people with visual impairment tend to have
longer hospital stays for co-existing morbidities [46, 47]
whilst risk of falling is higher for the visually impaired, in-
evitably leading to more ‘hidden’ costs [48].
Within this modelling exercise we loosely defined pa-
tients to be in a severe disease state if the MD is worse
than -12 dB in the better eye. This threshold is not en-
tirely arbitrary because it approximately equates to a pa-
tient failing the VF component of legal fitness to drive in
the UK [34] and has been used in staging disease sever-
ity in COAG before. In those patients with VF loss better
than this threshold, proposed practice seems particularly
cost-effective. Patients with sight loss worse than this
threshold would likely be on maximum therapies anyway
and our model suggests it would be less cost-effective to
monitor them closely at the outset. This might appear
controversial but it simply reflects the limited treatment
options in late stage glaucoma. Interestingly the idea that
surgery ought to always be the primary treatment option
for people diagnosed with advanced glaucoma is being
tested in an on-going large randomised trial in the UK
(https://www.tagsstudy.co.uk/).
Proposed practice is more cost-effective in younger pa-
tients (Table 2). This is unsurprising because the costs of
proposed practice are more likely to be recovered for a
person with longer residual life expectancy, with the
economic argument of early investment in preserving fu-
ture vision. More intensive monitoring of these patients
is obviously worthwhile in order to establish speed of
loss and improve their clinical management. Yet recent
research indicates that frequency of monitoring in clinics
in England does not vary by the age of the patient (or
rate of loss or disease severity for that matter) - younger
and older patients simply get the same diet of VF testing
[25]. Therefore, and at the very least, our model provides
evidence for the potential cost-effectiveness of stratifying
patients to more or less monitoring and this is an im-
portant conclusion from our work. A prospective re-
search study examining this issue is recommended. At
the moment, there is a tendency to have a ‘one size fits
all’ approach to monitoring the diagnosed patients and
this is likely a suboptimal method for monitoring large
cohorts of patients. In addition, previous modelling work
has indicated clustering tests at the beginning and end
of the initial 2-year period after diagnosis, rather than
evenly spaced VFs, will identify more rapid VF progres-
sion with fewer false positives. [18] Again, a prospective
study examining the health economics and benefits to
patients of using this approach is recommended.
Sensitivity analysis identified implementation costs as
the most important parameter impacting upon the
ICER, resulting in ICERs ranging from £8,400/QALY at
its minimum value to £24,700/QALY at its maximum
value. A full costing study examining the range of values
is clearly required to truly ascertain whether this max-
imum value is accurate or if there is already sufficient
excess capacity to allow for the proposed practice (the
minimum modelled assumption). The second most im-
portant parameter within the sensitivity analysis was the
costs of visual impairment. The minimum assumption of
costs to society equalling £0 resulted in a maximum
ICER of £21,400. However this perceived minimum limit
is unlikely to be representative in the real world espe-
cially given what an economist would refer to as the
negative externalities associated with glaucoma. We
therefore reiterate the message about the need for fur-
ther studies to estimate these costs more precisely [33];
without them the predictions from health economic
models of age-related eye disease will always lack preci-
sion. Costs associated with the 1st line of treatment
modelled within this study were identified as the third
most important factor within the Tornado analysis with
the lowest assumed value (£389) resulting in an ICER of
£17,800. As proposed practice accelerates the time it takes
to get an ‘upgrade’ in treatment modality provision,
patients are therefore moved away from the 1st line
of treatment at an increased rate. If costs for the 1st
line of treatment are relatively low, it becomes less
economically efficient to move to the 2nd and 3rd line
of treatment, therefore making the proposed practice
less cost-effective. This result points to the need for
better data on true costs of treatment for glaucoma
and this is worthy of further research, especially the
‘one off ’ cost for a surgical intervention compared to
long-term use of medical therapy.
A comprehensive study comparing resource utilisation
in the management of COAG in two cities in Finland
yielded interesting results that contradict some of the
findings in our work [49]. In particular more intensive
patient monitoring, over an 11-year period, did not seem
to benefit patients. Results, albeit based on a retrospective
analysis of data from relatively small populations, indi-
cated increased resource allocation did not lead to meas-
urable benefits to patients in terms of less glaucoma-
induced visual disability or self-reported quality of life. It
is noteworthy that increased resource allocation was due
mainly to increased treatment costs rather than increased
monitoring per se. This report, like ours, concluded a
prospective study is required to truly examine the
benefits of more or less monitoring in groups of patients
with COAG.
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Intensive monitoring of a chronic disease and acting on
detection of progression becomes more important if there
are a range of options to intensify treatment; this isn’t
really the case with COAG. For example, in our model we
only had three lines of ranked treatment options; a realis-
tic scenario given lack of treatment options in COAG.
After all, the only modifiable risk factor for disease pro-
gression is reduction of IOP. Some carefully done health
economic modelling work has demonstrated increased
cost effectiveness by aiming for a low IOP (standard IOP
< 15 mmHg) in all COAG patients after diagnosis; this in
turn would remove demand for intensive monitoring and
reduce the need for frequent VF testing. [50–52]
Limitations of the study
It is difficult to accurately model real world clinical deci-
sion making. Here clinical decision pathways were devel-
oped in consultation with two practicing glaucoma
specialists [19]. Decision making varies from clinician to
clinician however and it is possible that a clinical review
panel made up of different ophthalmologists could have
resulted in alternative decision nodes being constructed.
In addition, we only implemented three possible treatment
lines for simplicity but in reality there are significantly
more possible variations in treatment lines that the patients
could undergo. Moreover, our model did not account for
impact of co-pathology on outcomes for glaucoma therapy;
this thorny issue awaits a further study.
Critically our model does not consider the effect of
false positive decisions on VF progression. After all, it
has been shown that increasing VF testing will inevitably
affect specificity [18]. Therefore, with proposed practice
patients may receive intensified treatment when it is not
required and our model is not adjusted for this cost.
Our model has also made many necessary assumptions
about the costs of additional visual field testing. More-
over it assumes that all patients can provide reliable VF
results when many do not.
Our model only considered VF monitoring and not
the other assessments that need to be made during glau-
coma follow-up. For example, there are certainly inter-
esting open research questions about frequency of
monitoring and imaging the optic nerve or retinal nerve
fibre layer as surrogates for disease progression in
COAG, either in tandem with VF assessment or alone.
Our model also assumed the VF changes in a linear fash-
ion only. This is reasonable given work done in this area
[53] but deterioration to noticeable binocular vision loss
may be more suddenly noticed in patients [2].
One of the main limitations of this study consists of
implementing health state utility values derived from a
small number of people: 37 patients with mild COAG
(0.8015), 14 patients with moderate COAG (0.7471) and
just 9 patients with severe COAG (0.7133). Other health
economic models of health service delivery of COAG
have used different estimates for comparable health state
utility values [49, 51, 54]. There does not seem to be a
consistent approach, or optimal study design, for gener-
ating these values. We suggest this represents a signifi-
cant gap in knowledge for an important component of
health economic modelling for COAG.
An economic evaluation using discrete event simula-
tion might also model the process more accurately and
this has been used elsewhere [52]. Still, such models are
complex and difficult to interpret and a Markov model
structure offers simplicity and transparency.
Our model is likely also limited by the way in which dis-
ease severity was categorised - more work is needed to es-
tablish meaningful stratification of functional loss in
glaucoma. Our results only considered a summary meas-
ure from the VF. Research has shown that an index like
MD does not capture location and spatial extent of VF
loss in patients [2]. For example, two patients with the
same MD might have different visual function. Moreover,
there is debate about using a measure of binocular VF loss
and aligning this with utilities [35, 36]. Finally, our model
does not capture the co-morbidities of patients; this could
be concomitant eye disease or other chronic conditions.
Future research
Measuring impact of visual function loss on quality of
life requires further study in order to test the clinical-
and cost-effectiveness of health service delivery of
COAG [55]. Further research to quantify the costs of
sight impairment is also a priority. Also, little is known
about how patients adapt to gradual sight loss in glau-
coma and this subject is worthy of further study; we
speculate that this could have a significant bearing on
estimating utilities in health economic models for
COAG [56]. Indeed we suggest there are clear uncer-
tainties surrounding the utilities in these models despite
exemplar studies attempting to derive meaningful values
[40, 54]. New research should look at the precision and
accuracy of these values. Furthermore, whilst a range of
‘theoretical’ implementation costs were examined in the
sensitivity analysis of our model results, it was beyond
scope to examine in detail the costs associated with
implementing proposed practice; this clearly ought to be
the subject of further research along with consideration of
the thoughts on increased testing of patients and clini-
cians [23, 57]. Consideration of innovative and affordable
health service delivery redesign is likely to be a wider de-
bate that needs to be addressed too, as has been recently
suggested for people with ocular hypertension [58, 59].
Conclusion
Results from this modelling exercise indicate the health
economic benefits of intensifying monitoring of patients
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after they have been newly diagnosed with COAG. In-
creasing the number of VF examinations to better deter-
mine those patients’ that are rapidly losing vision appears
to be cost-effective; this might be particularly true for
younger patients. A study on the resource implications for
glaucoma follow-up and costs of sight impairment from
COAG would be worthwhile. A prospective study of
different follow-up patterns, especially stratified among
different patient groups is recommended.
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